Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 41344/0046.
Iloprost 100 micrograms/ml concentrate for solution for infusion
Iloprost 100 micrograms/ml concentrate for solution for infusion
1. What Iloprost 100 micrograms/ml is and what it is used for
2. What you need to know before you use Iloprost 100 micrograms/ml
3. How to use Iloprost 100 micrograms/ml
4. Possible side effects
5. How to store Iloprost 100 micrograms/ml
6. Contents of the pack and other information
Iloprost 100 micrograms/ml contains the active ingredient iloprost which imitates a natural substance in the body called prostacyclin. Iloprost 100 micrograms/ml and prostacyclin prevent unwanted blockages or narrowing of blood vessels and allow improved blood flow in the arteries.
Iloprost 100 micrograms/ml promotes the healing of wounds caused by insufficient blood flow (ischemia) by providing better oxygenation, and relieving pain in severe, chronic disorders of the blood circulation.
Iloprost 100 micrograms/ml is used in adults in the treatment of:
Talk to your doctor before using Iloprost 100 micrograms/ml if you:
After administration, when moving from a lying to upright position, your blood pressure may fall. This can make you feel dizzy for a while until your blood pressure returns to normal values (this is called "orthostatic hypotension"). Stand up slowly when you get out of bed.
This will help your body get used to this change in position and blood pressure.
If undiluted Iloprost 100 micrograms/ml is infused in the veins this can lead to local changes at the injection site due to extravasation.
Iloprost 100 micrograms/ml solution should not come into contact with your skin or eyes. On contact with the skin, iloprost may cause long-lasting but painless redness of the skin (erythema). In the event of such contact, wash immediately the skin or the eyes with water or saline.
Tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Iloprost 100 micrograms/ml and some other medicines may affect each other in the way they work in your body. Take special care to mention any of the following:
Iloprost 100 micrograms/ml is not indicated for pregnant or breast-feeding women.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Women of childbearing potential have to use effective contraception during treatment.
Iloprost 100 micrograms/ml lowers blood pressure and may cause dizziness or light-headedness in some people. Do not drive or operate any tools or machines if you feel these effects.
This medicine contains 8.1 mg of alcohol (96% ethanol) in each 1 ml. The amount in 1 ml of this medicine is equivalent to less than 1 ml beer or 1 ml wine. The small amount of alcohol in this medicine will not have any noticeable effects.
This medicine contains less than 1 mmol sodium (23 mg) per 1 ml, that is to say essentially ‘sodium free’.
Iloprost 100 micrograms/ml should be used only under strict monitoring in hospitals or out-patient clinics with adequate facilities.
Iloprost 100 micrograms/ml is a solution contained in a glass ampoule. The content of the ampoule is diluted with 0.9% physiological sodium chloride solution or a 5% glucose solution. The infusion solution should be prepared just before the infusion daily, to ensure sterility. The content of the ampoule and the diluent must be mixed thoroughly. Iloprost 100 micrograms/ml must be used only after dilution. For further information for physicians or healthcare professionals on the preparation of the dilution see section "The following information is intended for medical and healthcare professionals only" at the end of this leaflet.
The solution is infused intravenously with a venous catheter directly into one of the veins in your arm or into a central intravenous catheter inserted into a vein near your neck. Iloprost 100 micrograms/ml is administered as infusion over 6 hours daily.
The dose is adjusted according to individual tolerability within the range of 0.5 to 2.0 ng iloprost/kg body weight/min. Your blood pressure and heart rate will be measured at the start of the infusion and after every dose increase.
During the first 2-3 days, the individually tolerated dose is established.
For this purpose, your doctor will start the treatment at a low dose. Treatment should be started at an infusion rate of 0.5 ng/kg/min for 30 minutes. The dose should then be increased at intervals of 30 minutes in steps of 0.5 ng/kg/min up to 2.0 ng/kg/min. The exact infusion speed should be calculated on the basis of body weight to reach an infusion within the range of 0.5 to 2.0 ng/kg/min (see tables below for use with infusion pump or syringe driver).
If adverse effects occur, such as headache and nausea or an undesirable drop in blood pressure, tell your doctor immediately. The infusion rate should be reduced until the tolerable dose is found. If the adverse effects are severe, the infusion should be interrupted. For the remaining duration, the treatment should be continued with the dose found to be tolerated in the first 2 to 3 days.
The doctor will determine whether Iloprost 100 micrograms/ml will be infused intravenously by an infusion pump or with a syringe driver. If Iloprost 100 micrograms/ml is administered with an infusion pump, it will be diluted before infusion to a final concentration of 0.2 micrograms/ml. If Iloprost 100 micrograms/ml is administered with a syringe driver, it will be diluted before infusion to a final concentration of 2 micrograms /ml.
If you have renal failure requiring dialysis or liver cirrhosis, iloprost elimination is reduced and a dose reduction (e.g. half the recommended dose) is necessary. Tell your doctor if you have problems with your liver or kidneys.
The duration of treatment is up to 4 weeks.
The safety and efficacy of Iloprost 100 micrograms/ml have not been studied for treatment longer than 4 weeks or after repetitive treatment cycles.
Continuous infusion over several days is not recommended, because it can lead to reduced effect on platelets and increased platelet aggregation (platelet hyperaggregability) at the end of treatment. No clinical complications associated with these phenomena have been reported.
If you feel that the effect of Iloprost 100 micrograms/ml is too strong or too weak, tell your doctor or pharmacist.
If you have any further questions about the use of this product, ask your doctor or pharmacist.
Drop in blood pressure (hypotensive reaction) can be expected, as well as headache, redness of the face (flushing), nausea, vomiting and diarrhoea. An increase in blood pressure, reduced or increased heart rate and limb or back pain may also occur.
No specific antidote is known.
In case of overdose, your doctor is advised to discontinue infusion of iloprost, to monitor you and treat your symptoms.
If the infusion therapy with Iloprost 100 micrograms/ml is discontinued, your doctor will take care to restore the changes that might have been made to other medicines you take, due to Iloprost 100 micrograms/ml administration (e.g. dose reductions).
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most severe side effects, which have been reported as having a fatal or life-threatening effect in patients taking iloprost are:
The most common side effects observed in patients taking Iloprost 100 micrograms/ml include headache, flushing (redness of the face), hyperhidrosis (sweating) and gastrointestinal symptoms, such as nausea and vomiting. These side effects are likely to occur during the dose titration at the start of treatment to identify the best tolerable dose for the individual patient. However, all these side effects usually disappear quickly with dose reduction.
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 10,000 people)
Iloprost may cause chest pain or discomfort due to angina pectoris, especially in patients with coronary artery disease.
The risk of bleeding is increased in patients when inhibitors of platelet aggregation, heparin or anticoagulants of the coumarin-type are given concomitantly.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicinal product does not require any special storage conditions.
After opening and dilution: Chemical and physical in-use stability has been demonstrated for 24 hours at 25ºC. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8ºC, unless the dilution has taken place in controlled and validated aseptic conditions.
Do not use this medicine after the expiry date which is stated on the carton and ampoule label. The expiry date refers to the last day of that month.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment.
1 Box of 1 or 5 ampoules, each with 0.5 ml concentrate for solution for infusion or 1 box of 1 or 5 ampoules, each with 1 ml concentrate for solution for infusion.
Not all pack sizes may be marketed.
This leaflet was last revised in August 2023.
The latest approved patient information leaflet for this medicine is available via the following URL: https://www.medicines.org.uk/emc/product/10034/pil#about-medicine